MicroCHIPS begins testing implantable osteoporosis pump

MicroCHIPS of Bedford, MA, is initiating its first test for its implantable pump to deliver human parathyroid hormone marketed by Eli Lilly as Forteo, a drug that can actually rebuild bone in women with osteoporosis.

Mass High Tech reports that the trial comes some 18 years after MIT professor Robert Langer first envisioned using an implantable reservoir as a drug delivery device.

"MicroCHIPS' clinical study marks an important milestone in the comprehensive research and development of a new approach to drug delivery," said company co-founder Langer in a press release, "MicroCHIPS' breakthrough technologies have the ability to transform therapy in numerous disease states using active and responsive drug delivery devices."

Langer has said that he came up with the idea of using microprocessor-based implantable delivery systems while watching a documentary on microprocessors in 1993.

- read the report in Mass High Tech
- and another on Boston.com

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.